Compare VTGN & SOTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VTGN | SOTK |
|---|---|---|
| Founded | 1998 | 1975 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.8M | 72.1M |
| IPO Year | 2014 | 1995 |
| Metric | VTGN | SOTK |
|---|---|---|
| Price | $0.29 | $5.78 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 2 |
| Target Price | $1.00 | ★ $7.50 |
| AVG Volume (30 Days) | ★ 18.6M | 44.3K |
| Earning Date | 11-12-2026 | 10-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 37.50 |
| EPS | N/A | ★ 0.05 |
| Revenue | N/A | ★ $20,909,315.00 |
| Revenue This Year | $33.96 | $3.73 |
| Revenue Next Year | N/A | $10.38 |
| P/E Ratio | ★ N/A | $115.80 |
| Revenue Growth | N/A | ★ 1.97 |
| 52 Week Low | $0.20 | $3.40 |
| 52 Week High | $5.14 | $6.24 |
| Indicator | VTGN | SOTK |
|---|---|---|
| Relative Strength Index (RSI) | 58.49 | 69.22 |
| Support Level | $0.22 | $4.59 |
| Resistance Level | $0.32 | $6.24 |
| Average True Range (ATR) | 0.04 | 0.33 |
| MACD | 0.01 | 0.15 |
| Stochastic Oscillator | 25.01 | 86.92 |
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.
Sono-Tek Corp designs and manufactures ultrasonic coating systems for applying precise, thin film coatings to add functional properties, protect or strengthen surfaces on parts and components for the microelectronics/electronics, alternative energy, medical, industrial, and emerging research & development/other markets. The company designs and manufacture custom-engineered ultrasonic coating systems incorporating its patented technology, in combination with applications engineering knowledge, to assist its customers in achieving their desired coating solutions.